196 related articles for article (PubMed ID: 9129065)
1. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
Lafeuillade A; Poggi C; Tamalet C; Profizi N; Tourres C; Costes O
J Infect Dis; 1997 May; 175(5):1051-5. PubMed ID: 9129065
[TBL] [Abstract][Full Text] [Related]
2. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
3. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
4. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E;
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509
[TBL] [Abstract][Full Text] [Related]
6. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
[TBL] [Abstract][Full Text] [Related]
7. Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
Katzenstein DA; Hughes MD; Albrecht M; Liou SH; Murphy R; Balfour H; Para M; Hammer S;
AIDS Res Hum Retroviruses; 2001 Feb; 17(3):203-10. PubMed ID: 11177402
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.
Lafeuillade A; Tamalet C; Poggi C; Pellegrino P; Tourres C; Izopet J
AIDS; 1997 Jan; 11(1):67-72. PubMed ID: 9110077
[TBL] [Abstract][Full Text] [Related]
9. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
10. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
Tamalet C; Lafeuillade A; Fantini J; Poggi C; Yahi N
AIDS; 1997 Jun; 11(7):895-901. PubMed ID: 9189215
[TBL] [Abstract][Full Text] [Related]
11. Virus burden in lymph nodes and blood of subjects with primary human immunodeficiency virus type 1 infection on bitherapy.
Perrin L; Yerly S; Marchal F; Schockmel GA; Hirschel B; Fox CH; Pantaleo G
J Infect Dis; 1998 Jun; 177(6):1497-501. PubMed ID: 9607825
[TBL] [Abstract][Full Text] [Related]
12. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
[TBL] [Abstract][Full Text] [Related]
14. Focusing on the second phase of plasma HIV-1 RNA clearance.
Lafeuillade A; Poggi C; Sayada C; Pellegrino P; Profizi N
AIDS; 1997 Feb; 11(2):264-6. PubMed ID: 9030385
[No Abstract] [Full Text] [Related]
15. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
Hirsch M; Steigbigel R; Staszewski S; Mellors J; Scerpella E; Hirschel B; Lange J; Squires K; Rawlins S; Meibohm A; Leavitt R
J Infect Dis; 1999 Sep; 180(3):659-65. PubMed ID: 10438352
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
[TBL] [Abstract][Full Text] [Related]
18. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Lafeuillade A; Poggi C; Profizi N; Tamalet C; Costes O
J Infect Dis; 1996 Aug; 174(2):404-7. PubMed ID: 8699075
[TBL] [Abstract][Full Text] [Related]
19. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
[TBL] [Abstract][Full Text] [Related]
20. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection.
Poggi C; Profizi N; Djediouane A; Chollet L; Hittinger G; Lafeuillade A
AIDS; 1999 Jul; 13(10):1213-20. PubMed ID: 10416525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
